Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors
HematologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Haemophilia : the official journal of the World Federation of Hemophilia
- Publicado em
- 17 jul 2025
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors
Manuel Carcao, Cédric Hermans, Adam Giermasz, Craig Kessler, Wolfgang Miesbach, Doris Quon, Jerzy Windyga, Johnny Mahlangu
Descritores MeSH
- Hemophilia A
- Factor VIIa
- Hemophilia B
- Female
- Humans
- Male
- Middle Aged
- Recombinant Proteins
- Adolescent
- Young Adult
Veja também
Estudos relacionados
- Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors
- Chinese guidelines on the treatment of hemophilia (2025)
- Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors: A systematic literature review
- Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors